Loading...
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Martin, M Holmes, Ejlertsen, B Delaloge, S Moy, B Iwata, H von Minckwitz, G Chia, S Mansi, J Barrios, C
Martin, M
Holmes,
Ejlertsen, B
Delaloge, S
Moy, B
Iwata, H
von Minckwitz, G
Chia, S
Mansi, J
Barrios, C
Citations
Altmetric:
Abstract
ExteNET showed that 1 year of neratinib, an irreversible pan-HER tyrosine kinase inhibitor, significantly improves 2-year invasive disease-free survival after trastuzumab-based adjuvant therapy in women with HER2-positive breast cancer. We report updated efficacy outcomes from a protocol-defined 5-year follow-up sensitivity analysis and long-term toxicity findings.
Authors
Martin, M
Holmes,
Ejlertsen, B
Delaloge, S
Moy, B
Iwata, H
von Minckwitz, G
Chia, S
Mansi, J
Barrios, C
Gnant, M
Tomašević, Z
Denduluri, N
Šeparović, R
Gokmen, E
Bashford, A
Ruiz Borrego, M
Kim, S
Jakobsen, E
Ciceniene, A
Inoue, K
Overkamp, F
Heijns, J
Armstrong, Anne C
Link, J
Joy, A
Bryce, R
Wong, A
Moran, S
Yao, B
Xu, F
Auerbach, A
Buyse, M
Chan, A
Holmes,
Ejlertsen, B
Delaloge, S
Moy, B
Iwata, H
von Minckwitz, G
Chia, S
Mansi, J
Barrios, C
Gnant, M
Tomašević, Z
Denduluri, N
Šeparović, R
Gokmen, E
Bashford, A
Ruiz Borrego, M
Kim, S
Jakobsen, E
Ciceniene, A
Inoue, K
Overkamp, F
Heijns, J
Armstrong, Anne C
Link, J
Joy, A
Bryce, R
Wong, A
Moran, S
Yao, B
Xu, F
Auerbach, A
Buyse, M
Chan, A
Description
Date
2017-12
Publisher
Collections
Keywords
Type
Article
Citation
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. 2017, 18(12): 1688-1700 Lancet Oncol